Shanghai Allist Pharmaceuticals Co. Ltd. A
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China. Its lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC), as well as for treating adult patients with locally advanced or metastatic NSCLC. The co… Read more
Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) - Net Assets
Latest net assets as of September 2025: CN¥6.50 Billion CNY
Based on the latest financial reports, Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) has net assets worth CN¥6.50 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.26 Billion) and total liabilities (CN¥760.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥6.50 Billion |
| % of Total Assets | 89.52% |
| Annual Growth Rate | 45.57% |
| 5-Year Change | 83.56% |
| 10-Year Change | N/A |
| Growth Volatility | 544.3 |
Shanghai Allist Pharmaceuticals Co. Ltd. A - Net Assets Trend (2017–2024)
This chart illustrates how Shanghai Allist Pharmaceuticals Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shanghai Allist Pharmaceuticals Co. Ltd. A (2017–2024)
The table below shows the annual net assets of Shanghai Allist Pharmaceuticals Co. Ltd. A from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.28 Billion | +32.66% |
| 2023-12-31 | CN¥3.98 Billion | +24.95% |
| 2022-12-31 | CN¥3.19 Billion | +7.19% |
| 2021-12-31 | CN¥2.97 Billion | +3.31% |
| 2020-12-31 | CN¥2.88 Billion | +143.00% |
| 2019-12-31 | CN¥1.18 Billion | +1567.31% |
| 2018-12-31 | CN¥71.04 Million | -81.37% |
| 2017-12-31 | CN¥381.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Allist Pharmaceuticals Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 306.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.24 Billion | 23.57% |
| Common Stock | CN¥450.00 Million | 8.52% |
| Other Components | CN¥3.59 Billion | 67.92% |
| Total Equity | CN¥5.28 Billion | 100.00% |
Shanghai Allist Pharmaceuticals Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Shanghai Allist Pharmaceuticals Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TUI AG
PINK:TUIFF
|
$2.90 Billion |
|
Focuslight Technologies Inc. A
SHG:688167
|
$2.90 Billion |
|
Sumitomo Heavy Industries Ltd
F:SSM1
|
$2.90 Billion |
|
Kinsus Interconnect Technology Corp
TW:3189
|
$2.90 Billion |
|
Dyne Therapeutics Inc
NASDAQ:DYN
|
$2.89 Billion |
|
Indivior PLC Ordinary Shares
NASDAQ:INDV
|
$2.89 Billion |
|
Hannover Re
PINK:HVRRY
|
$2.89 Billion |
|
Red Rock Resorts Inc
NASDAQ:RRR
|
$2.89 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Allist Pharmaceuticals Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,982,277,872 to 5,282,813,244, a change of 1,300,535,372 (32.7%).
- Net income of 1,429,847,084 contributed positively to equity growth.
- Dividend payments of 292,500,000 reduced retained earnings.
- Other factors increased equity by 163,188,288.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥1.43 Billion | +27.07% |
| Dividends Paid | CN¥292.50 Million | -5.54% |
| Other Changes | CN¥163.19 Million | +3.09% |
| Total Change | CN¥- | 32.66% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Allist Pharmaceuticals Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.04x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 89.58x to 8.04x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥1.06 | CN¥94.51 | x |
| 2018-12-31 | CN¥0.20 | CN¥94.51 | x |
| 2019-12-31 | CN¥2.63 | CN¥94.51 | x |
| 2020-12-31 | CN¥6.40 | CN¥94.51 | x |
| 2021-12-31 | CN¥6.61 | CN¥94.51 | x |
| 2022-12-31 | CN¥7.08 | CN¥94.51 | x |
| 2023-12-31 | CN¥8.84 | CN¥94.51 | x |
| 2024-12-31 | CN¥11.75 | CN¥94.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Allist Pharmaceuticals Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 27.07%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 40.19%
- • Asset Turnover: 0.60x
- • Equity Multiplier: 1.12x
- Recent ROE (27.07%) is above the historical average (-17.96%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -10.21% | -503.87% | 0.02x | 1.33x | CN¥-77.06 Million |
| 2018 | -137.10% | -2108.11% | 0.01x | 5.28x | CN¥-104.50 Million |
| 2019 | -33.56% | -63123.39% | 0.00x | 1.12x | CN¥-515.94 Million |
| 2020 | -10.79% | -55361.45% | 0.00x | 1.04x | CN¥-598.32 Million |
| 2021 | 0.61% | 3.45% | 0.17x | 1.05x | CN¥-279.05 Million |
| 2022 | 4.10% | 16.50% | 0.23x | 1.08x | CN¥-188.18 Million |
| 2023 | 16.18% | 31.92% | 0.46x | 1.10x | CN¥245.95 Million |
| 2024 | 27.07% | 40.19% | 0.60x | 1.12x | CN¥901.57 Million |
Industry Comparison
This section compares Shanghai Allist Pharmaceuticals Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) | CN¥6.50 Billion | -10.21% | 0.12x | $2.90 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |